NASH vs Alcohol Cirrhosis: Transplant Outcomes Compared

Research-informed explainer — last updated April 2026

NASH cirrhosis and alcohol-related cirrhosis now account for most liver transplants in the United States, and the registry data show their post-transplant survival rates are roughly comparable — but the path to transplant and the risks that follow differ in meaningful ways. NASH (nonalcoholic steatohepatitis, now often called MASLD — metabolic dysfunction-associated steatotic liver disease) tends to affect older patients with diabetes and obesity, which raises the stakes for surgical complications. Alcohol-related cirrhosis has its own set of hurdles, including sobriety requirements and a real risk of recidivism post-transplant. Knowing how these two diseases compare can help you understand what your transplant team is evaluating and what questions to ask.

This explainer draws on peer-reviewed research from four transplant hepatologists listed in the Convene directory. Allison Kwong, MD, at Stanford Medicine co-leads the OPTN/SRTR Annual Data Reports on liver transplantation — the most comprehensive national registry on who gets listed, who gets transplanted, and what happens afterward [1][2][3][4]. Mary Rinella, MD, at UChicago Medicine co-led the 2023 multisociety consensus renaming NAFLD/NASH as MASLD/MASH, and led the 2023 AASLD practice guidance on fatty liver disease [6][7][8]. Vijay Shah, M.D., at Mayo Clinic co-authored the Baveno VII portal hypertension consensus and validated the MELD score in alcoholic liver disease [10][11]. Sammy Saab, MD, at UCLA Pfleger Liver Institute published a landmark analysis of 3,200 liver transplant outcomes over two decades and co-authored foundational work on MELD-sodium scoring [12][13][14].

What is NASH cirrhosis (now called MASH)?

NASH stands for nonalcoholic steatohepatitis. It is a form of fatty liver disease where fat builds up in liver cells, triggers inflammation, and — over years — causes scarring (fibrosis) that can progress to cirrhosis. In 2023, a multisociety Delphi consensus process involving 236 experts from 56 countries agreed to rename this condition MASLD (metabolic dysfunction-associated steatotic liver disease) and the more severe inflammatory form MASH [6]. The old name, NAFLD/NASH, was seen as stigmatizing and imprecise; the new one links the disease to its actual cause — metabolic dysfunction driven by obesity, type 2 diabetes, high blood pressure, and elevated triglycerides.

A 2021 Lancet review put global NAFLD/MASLD prevalence at roughly 25–30% of adults, making it one of the most common liver conditions worldwide [9]. Most people with fatty liver never progress to cirrhosis. But a meaningful fraction do, and MASLD-related cirrhosis is now one of the fastest-growing indications for liver transplant evaluation in the United States [1][2].

The AASLD 2023 practice guidance — led by Mary Rinella and covering more than 1,400 publications since the last major update in 2018 — emphasizes that disease progression is hard to predict at the individual level [7]. Some patients move from simple fatty liver to cirrhosis over 10–15 years; others never do. Diabetes, obesity, and worsening fibrosis on biopsy are the strongest signals that someone is heading toward end-stage disease.

What is alcohol-related cirrhosis?

Alcohol-related cirrhosis develops when years of heavy drinking damage and scar liver tissue beyond its capacity to regenerate. Like MASLD-related cirrhosis, the end result is the same functional collapse — portal hypertension, variceal bleeding, ascites, hepatic encephalopathy — but the underlying biology and the transplant evaluation process differ.

Vijay Shah and colleagues validated the MELD scoring system in patients with alcoholic hepatitis, showing a MELD score of 21 predicted 30-day and 90-day mortality with 75% sensitivity and specificity in a cohort of 73 patients followed at Mayo Clinic [11]. That work helped establish MELD as a reliable severity marker across alcohol-related liver disease, not just the broader cirrhosis population.

The Baveno VII consensus statement, co-authored by Shah and published in the Journal of Hepatology in 2021, outlines how portal hypertension — the elevated pressure inside the liver's vein system that causes most life-threatening complications in cirrhosis — should be assessed and managed across etiologies [10]. Portal hypertension itself behaves similarly regardless of whether the underlying cause is alcohol, MASLD, or something else, but the pace of decompensation and the patient's overall health picture can differ substantially.

How the two compare for transplant evaluation

For patients with either disease, being listed for transplant requires reaching a minimum disease severity threshold. The primary tool is the MELD score (Model for End-Stage Liver Disease), which uses bilirubin, creatinine, INR, and sodium to estimate 90-day mortality risk without a transplant. MELD 3.0 — published in Gastroenterology in 2021 and co-authored by Allison Kwong — updated the original model to better capture women's risk, who were systematically under-prioritized under the old scoring system [5].

MELD-sodium, validated in a multi-center study co-authored by Sammy Saab and published in Gastroenterology in 2006, adds serum sodium to the equation because hyponatremia (low sodium) signals fluid dysregulation that the original MELD did not capture [14]. Both MELD and MELD-sodium are used by transplant programs to rank waitlist candidates, meaning your score — not your diagnosis — determines your priority.

One practical difference between the two diseases involves the sobriety requirement. Most U.S. transplant programs historically required six months of documented abstinence before listing a patient with alcohol-related liver disease. That rule has been increasingly questioned as evidence accumulates that recidivism rates after transplant are not reliably predicted by pre-transplant sobriety duration alone. Some programs now use individualized psychosocial assessments rather than rigid time requirements. For MASLD patients, there is no equivalent sobriety policy, though transplant teams look closely at whether the metabolic conditions driving the disease — diabetes, obesity, high blood pressure — are being managed, since uncontrolled metabolic disease affects surgical risk and long-term outcomes.

At a glance

What the registry data show

The OPTN/SRTR Annual Data Reports, co-authored by Allison Kwong, are the most detailed public records of liver transplantation in the United States. They track every patient listed for transplant, every organ allocated, and every outcome through five years post-transplant across more than 100 active transplant programs.

Over the 2018–2021 reporting period, NASH/MASLD steadily grew as a transplant indication. It overtook hepatitis C as a leading cause of transplant in many demographic groups, reflecting the success of hepatitis C cure therapy and the ongoing rise of metabolic liver disease in the U.S. population [1][2][3][4]. Alcohol-related liver disease also grew substantially over the same period, in part because programs have become more willing to evaluate carefully selected patients without rigid sobriety requirements.

Post-transplant graft survival data show that outcomes for NASH and alcohol-related cirrhosis track closely with outcomes for other major indications. The 2021 annual report data show no clear inferiority for either etiology when patients are appropriately selected [1]. The bigger differentiators are recipient age and comorbidity burden — both of which tend to be higher in the MASLD population — rather than the underlying liver disease itself.

Sammy Saab and colleagues published a 20-year analysis of more than 3,200 liver transplantations at a single center, finding that pediatric and non-urgent patients had the best long-term outcomes, and that multiple recipient factors — not just etiology — drove survival differences [12]. A follow-up study from the same group found that more than 50% of recipients survive 20 years after transplant and report quality of life better than patients managing chronic liver disease or other serious conditions [13]. These figures apply across etiologies, including NASH and alcohol-related disease, when patients are selected appropriately.

What MASLD patients face after transplant

Metabolic comorbidities do not disappear after a liver transplant. In fact, immunosuppressive medications — particularly corticosteroids and calcineurin inhibitors given to prevent rejection — can worsen insulin resistance, promote weight gain, and raise blood pressure. MASLD patients who already carry those risks before transplant may find them amplified in the first one to three years post-transplant.

The 2023 AASLD practice guidance notes that recurrent steatosis in the transplanted liver is common in MASLD patients who do not address the underlying metabolic factors — diet, physical activity, and medication management of diabetes and blood pressure [7]. True recurrent cirrhosis from MASLD alone is rare in the medium term, but it is a long-term concern in patients who gain significant weight or develop worsening diabetes after transplant. Transplant hepatologists typically involve endocrinology and nutrition teams early in the post-transplant period to manage this risk proactively.

The 2023 Delphi nomenclature consensus — which Mary Rinella led — noted that the new MASLD terminology better captures the metabolic underpinning of the disease and should improve how clinicians communicate risk to patients [6]. For you as a patient, the practical implication is that your transplant team is not just treating your liver; they are treating the metabolic syndrome that caused the liver problem in the first place.

What alcohol-related cirrhosis patients face after transplant

Recidivism — returning to drinking after transplant — is the central concern for alcohol-related cirrhosis. Estimates vary widely depending on how it is measured and how long patients are followed, but roughly 20–25% of transplant recipients with alcohol-related disease resume alcohol use at some point post-transplant, and a smaller fraction return to heavy drinking. Most transplant programs have addiction medicine specialists or social workers embedded in the transplant team specifically to support patients through the transition.

Graft outcomes for patients who return to heavy drinking after transplant are substantially worse than for those who maintain abstinence. But for the majority who do maintain sobriety, survival and quality of life outcomes are comparable to recipients transplanted for other causes [12][13]. The 2021 OPTN/SRTR data confirms that alcohol-related liver disease as a transplant indication is not associated with inferior graft survival at one or three years when the analysis accounts for other patient factors [1].

Portal hypertension management in the pre-transplant period matters for both groups. The Baveno VII consensus — co-authored by Vijay Shah — provides guidance on screening for esophageal varices, primary prophylaxis with non-selective beta-blockers, and the role of non-invasive liver stiffness measurement to reduce the need for invasive hemodynamic testing [10]. Both MASLD-cirrhosis and alcohol-related cirrhosis patients benefit from being connected to a transplant hepatologist early enough to implement these protocols before acute decompensation.

How MELD score works for both

The MELD score does not distinguish between etiologies — it measures functional severity, not cause. A MASLD patient with a MELD of 24 and a patient with alcohol-related cirrhosis at MELD 24 face the same listing priority. The score uses three lab values (bilirubin, creatinine, INR) plus sodium in the MELD-sodium version [14], and was updated in MELD 3.0 to include a sex-specific adjustment that helps correct for the historical underestimation of women's waitlist mortality [5].

For MASLD patients, the MELD score can be deceptive in the early stages. The disease often progresses slowly and silently, with MELD staying in the low-to-mid range for years until an acute event — an infection, a gastrointestinal bleed, a hospitalization — triggers rapid decompensation. Alcohol-related cirrhosis can follow a similar slow course, but patients with active or recent heavy drinking can experience acute-on-chronic liver failure, where MELD rises sharply over days to weeks. Some programs now accept these patients for transplant even without a long period of pre-transplant sobriety if the prognosis without transplant is clearly dire and the psychosocial evaluation is favorable.

Questions to ask your transplant hepatologist

• Given my specific cause of cirrhosis, what is my MELD score today and what score typically triggers active waitlisting at your program?
• If I have MASLD, what can I do now to slow disease progression and reduce surgical risk before I might need a transplant?
• If I have alcohol-related cirrhosis, what does your program's sobriety evaluation process involve, and what support services do you offer?
• What metabolic conditions — diabetes, obesity, blood pressure — do I need to have better controlled before transplant evaluation?
• How does your program track graft outcomes for MASLD versus alcohol-related disease, and what does your center's data show?
• After a transplant for my diagnosis, what does long-term follow-up look like, and who manages my metabolic health?

The bottom line

NASH cirrhosis (now called MASH under the MASLD umbrella) and alcohol-related cirrhosis are now the two most common reasons adults in the United States need a liver transplant. Post-transplant survival rates for both are comparable to other major indications when patients are appropriately selected. The differences show up in the path to listing — metabolic comorbidities and cardiovascular risk for MASLD, sobriety evaluation and addiction support for alcohol-related disease — and in the long-term management after surgery, where MASLD patients need careful metabolic monitoring and alcohol-related cirrhosis patients need sustained sobriety support. The MELD score prioritizes both groups equally based on severity, not cause. Getting evaluated early at a transplant center, rather than waiting until a crisis, gives patients the best chance at a favorable outcome regardless of which disease brought them there.